Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Tandem Isotope Therapy with225Ac- and177Lu-PSMA-617 in a Murine Model of Prostate Cancer | Synapse

October 5, 2023Open Access

Tandem Isotope Therapy with225Ac- and177Lu-PSMA-617 in a Murine Model of Prostate Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Ac in this model suggests a preference for α-emitters alone, or possibly in combination, in the microscopic disease setting.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Meyer et al. (Thu,) studied this question.

synapsesocial.com/papers/6a00ea1ff9e1acab462d76c2 https://doi.org/https://doi.org/10.2967/jnumed.123.265433

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.2005 · 247 citations
2MIRD: Radionuclide Data and Decay Schemes2009 · 126 citations
3Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications2008 · 214 citations
4Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study2020 · 29 citations
5[177Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography2019 · 64 citations